Therapeutic effects and molecular mechanisms of anti-fibrosis herbs and selenium on rats with hepatic fibrosis

Table 1 Histological grading of hepatic fibrosis

Group	Grade o	Grade I	Grade II	Grade III	Grade IV
Normal	10	0	0	0	0
Model	0	0	0	0	8c
Colchicine	0	1	3	4	1c
AF	4	3	1	1	0a
AS	3	3	2	1	0ac

^aP < 0.05, vs colchicine group;

^cP < 0.05, vs normal control group.

Table 2 Serum content of ALT, AST, HA and LN

Group	ALT (u/L)	AST (u/L)	HA (µg/L)	LN (µg/L)
Normal	52.5 ± 9.2a	137.8 ± 18.7a	178 ± 58a	59.8 ± 21.8a
Model	165.6 ± 32.7ace	257.4 ± 22.6c	550 ± 68c	130.0 ± 30.5c
Colchicine	96.2 ± 20.9c	215.8 ± 24.6c	416 ± 135c	106.3 ± 14.2c
AF	65.8 ± 26.5a	150.8 ± 34.0a	228 ± 83ac	85.9 ± 15.0c
AS	67.3 ± 18.4a	154.6 ± 27.3a	216 ± 58ac	80.6 ± 18.6c

^aP < 0.05, vs colchicine group;

^cP < 0.05, vs normal control group;

^eP > 0.05, vs control group.

Table 3 Content of CD₄ and CD₈ in thymus

Group	Rats	CD4(%)	CD8(%)	CD4/CD8
Normal	10	54.1 ± 1.4a	34.1 ± 1.2	1.58
Model	8	40.2 ± 2.1c	31.7 ± 1.3	1.26c
Colchicine	9	42.1 ± 2.0c	32.1 ± 0.9	1.31c
AF	9	50.8 ± 3.8a	34.8 ± 2.1	1.45
AS	9	52.6 ± 3.4a	35.9 ± 2.2	1.46

^aP < 0.05, vs Colchicine group;

^cP < 0.05, vs normal control group.

Table 4 Level of TGF-β₁ mRNA in relation to GAPDH

Group	Rats	Ratio
Normal	10	0.57 ± 0.11
Model	8	2.34 ± 0.43c
Colchicine	9	1.88 ± 0.21c
AF	9	1.07 ± 0.31a
AS	9	0.98 ± 0.21a

^aP < 0.05, vs Colchicine group;

^cP < 0.05, vs normal control group.